Back to News
Jan 9, 2026 8:00 PM

KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch.

• KalVista Pharmaceuticals stock is approaching key resistance levels. Why did KALV hit a new high?

In July 2025, the U.S. Food and Drug Administration (FDA) approved Ekterly for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and ...